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Endovascular or Surgical Treatment for Carotid Artery Stenosis?*The management of carotid atherosclerosis remains
one of the most controversial areas of vascular prac-
tice despite attracting more randomised trials than
any other problem in peripheral artery disease. Pres-
ently the most hotly debated topic is carotid stenting.
Over the last decade there has been an increasing shift
towards the endovascular treatment of most vascular
beds. In many countries this also applies to the treat-
ment of carotid stenosis. In this issue of The European
Journal of Vascular and Endovascular Surgery Luebke
and colleagues present a meta-analysis of trials com-
paring endovascular and surgical treatment of carotid
stenosis. The main findings are that endovascular
therapy was associated with increased risk of peri-
operative stroke, OR 1.50 (95% 1.05e2.16), but a re-
duced risk of cranial nerve injury, OR 0.15 (95% CI
0.09e0.26).1 No difference in outcome at one year
was found, however, few of the studies have as yet re-
ported at this time point. Based on these findings the
authors concluded that endarterectomy remains the
‘‘gold standard’’ in the treatment of carotid stenosis
and carotid stenting should only be carried out as
part of an on-going randomised trial. It should be
noted that the authors finding of a worse periopera-
tive outcome in patients randomised to endovascular
intervention only held for a fixed effect model and
was not demonstrated with the statistically more
conservative random effect model.1
An earlier meta-analysis by Coward and col-
leagues reached similar conclusions, although no
difference in perioperative stroke rate was found.2
This study preceded two of the trials included in
the present analysis.3,4 Of the seven trials examined
in the meta-analysis of Luebke et al., five contributed
most of the patients (Table 1).3e7 Examination of the
perioperative outcomes from these studies demon-
strates a number of important points. Firstly, the
findings of the five trials are quite variable. One trial
found a significant two-fold higher perioperative
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(project grant 379600, fellowship 431503).1078–5884/000480+ 03 $32.00/0  2007 Published by Elsevier Ltd ostroke and death rate in patients randomised to
endovascular intervention.4 Another smaller trial
reported similar findings which were of borderline
statistical significance.6 The findings of the later
study have only been reported in abstract form mak-
ing examination of this trial problematic.6 The other
threemain trials, including the largest study involving
approximately 1200 patients, reported no difference in
the main 30 day outcome between surgery and endo-
vascular treatment (Table 1).3,5,7 The 30 day stroke
and death rate varied from 5.4 to 12.1% in patients
receiving endovascular intervention and 3.8 to 9.9%
in those treated by surgery (Table 1).
This variability in outcome is quite concerning. The
stroke-mortality rate in six of the 10 intervention
groups from these five trials is higher than in any of
the intervention groups from the original trials, which
demonstrated the value of carotid endarterectomy
over medical treatment (Table 1).8e11 This finding is
even more concerning when it is appreciated that
three of the four trials which compared endarterec-
tomy to medical therapy were completed in the
1990s when the value of anti-platelet medication, sta-
tins, Angiotensin II inhibition and b-blockade were
less clear.8,10,11 Thus it is likely that the outcome for
symptomatic carotid atherosclerosis treated by best
medical therapy alone today would be considerable
better than reported in NASCET and ECST.10,11
The stroke-mortality rates reported in the trials
comparing endovascular and surgical treatment of
carotid stenoses are well outside the thresholds
acceptable for asymptomatic carotid intervention
(Table 1). Although only one trial included a signifi-
cant number of asymptomatic patients (71% in
SAPPHIRE), it is hard to imagine that either interven-
tion is adding much to the treatment of asymptomatic
carotid stenosis based on these independent physician
audited outcomes. As pointed out by Luebke and
colleagues, endovascular therapy of carotid athero-
sclerosis is an evolving therapy. Placement of stents
has now become standard, as has dual anti-platelet
therapy. Cerebral protection devices are increasingly
used for endovascular carotid stenting. The trialn behalf of European Society for Vascular Surgery.
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1with the highest rate of protection device use reported
the lowest perioperative stroke rate.7 EVA-3S however
had only a marginally lower protection device use but
almost double the stroke-mortality rate of the SAP-
PHIRE study.4 The good outcome in the SAPPHIRE
study may thus relate to the high percentage of
asymptomatic stenoses treated in that trial (Table 1).
Our conclusions must take into account the
evolving nature of endovascular therapy. The trials
presently on-going may give a more realistic appraisal
of the value of endovascular therapy in a setting
where technology and protocols have become more
established.12 It can however be noted from the table
that the perioperative endovascular outcomes were
little improved in the recent EVA-3S trial compared
to the first major trial in which no protective devices
were available and stenting was frequently not
performed.4,5 It would thus appear appropriate to
continue investigation of endovascular therapy for
symptomatic carotid atherosclerosis as part of on-
going trials which are already established. It would
presently appear inappropriate to treat asymptomatic
carotid atherosclerosis by endovascular means in
most instances. Indeed it remains uncertain that the
excellent perioperative outcomes reported for endar-
terectomy in ACAS and ACST can be reproduced in
general practice.8,9
Ultimately, the lesions for which endovascular ther-
apy is most appropriate may reflect the strength of
this technique and the weaknesses of endarterectomy.
Few would argue with the use of carotid stenting for
symptomatic restenosis, in the presence of past neck
irradiation or when the stenosis is surgically inacces-
sible. Endarterectomy is clearly more appropriate
however when the aortic arch is markedly unfolded
and atheromatous making an endovascular pathway
to the carotid artery hazardous.
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